Zymogenetics, Inc.

Mallinckrodt Pharma IP Trading D.a.c.

Ares Trading S.a.

Janine Bilsborough

Yue Yao

Cecile Krejsa

Mark Rogge

Linda Zuckerman

Richard I Senderoff

Kirk P Van Ness

Wayne J Wallis

Glen Martyn

Eliane Schutte

Alisa M Littau

Hans Otto Lennart Graffner

Rafael A Ponce, Jr

Matthew S Holdren

Claudia Pena Rossi

Jr Ponce Rafael A

Jr Rafael A Ponce

The present invention relates to novel formulations comprising a dry powder fibrin sealant comprised of a mixture of fibrinogen and/or thrombin, for use in the treatment of wounds or injuries, in particular for use as a topical hemostatic composition or for surgical intervention.

Formulations for wound therapy

The invention relates to novel combination therapies involving BLyS or BLyS/APRIL inhibition and immunosuppressants for the treatment of autoimmune diseases. One preferred method is where the BLyS and/or APRIL antagonist is a Fc-fusion protein which can be a TACI-Fc-fusion protein comprising the extracellular domain of TACI or a functional fragment thereof, a BAFF-R-Fc-fusion protein comprising the extracellular domain of BAFF-R or a functional fragment thereof, or a BCMA-Fc-fusion protein comprising the extracellular domain of BCMA or a functional fragment thereof. In the methods of the present invention some of the immunosuppressive drugs contemplated include cyclophosphamide (CYC), azathioprine (AZA), cyclosporine A (CSA), or mycophenolate mofetil (MMF), although any drug that suppresses the immune system may be suitable. The methods of the present invention reduce the levels of various immunoglobulins in patients in need of such reduction, such as those suffering from autoimmune diseases.

Combination of BLyS and/or APRIL inhibition and immunosuppressants for treatment of autoimmune disease

Growing community of inventors

Seattle, WA, United States of America

Linda Zuckerman